C1 Esterase Inhibitor Recombinant Brand Name– RUCONEST
What is C1 Esterase Inhibitor Recombinant
C1 esterase inhibitor recombinant is approved for the treatment of acute angioedema attacks in adolescents and adults with hereditary angioedema (HAE).
Effectiveness is not established in HAE patients with laryngeal attacks. HAE is a rare genetic disorder that presents as acute, recurrent attacks of soft tissue skin swelling, abdominal pain, and potentially life-threatening upper airway obstruction.
Patients with HAE have low concentrations of endogenous or functional C1 inhibitor, which is a plasma protein that maintains the natural regulation of the contact, complement, and fibrinolytic systems.
C1 esterase inhibitor, recombinant is a analog of human C1 esterase inhibitor and is obtained from the milk of rabbits expressing the gene encoding for human C1 esterase inhibitor.
C1 esterase inhibitor, recombinant is contraindicated in patients with a history of allergy to rabbits or rabbit-derived products.
C1 esterase inhibitor, recombinant was FDA-approved in July 2014.
- angioedema prophylaxis
- hereditary angioedema
For the treatment of acute attacks of hereditary angioedema (HAE)
- abdominal pain
- anaphylactoid reactions
- antibody formation
- back pain
- laboratory monitoring not necessary
- leporine protein hypersensitivity
- thromboembolic disease
There are no drug interactions associated with C1 Esterase Inhibitor Recombinant products.